ES2746558T3 - Activadores de piruvato cinasa R para uso en terapia - Google Patents
Activadores de piruvato cinasa R para uso en terapia Download PDFInfo
- Publication number
- ES2746558T3 ES2746558T3 ES12721111T ES12721111T ES2746558T3 ES 2746558 T3 ES2746558 T3 ES 2746558T3 ES 12721111 T ES12721111 T ES 12721111T ES 12721111 T ES12721111 T ES 12721111T ES 2746558 T3 ES2746558 T3 ES 2746558T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- pharmaceutically acceptable
- phenyl
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCC*C(C)(c1ccccc1)O Chemical compound CCC*C(C)(c1ccccc1)O 0.000 description 9
- CUWMMYFPUKXUKK-GZIVZEMBSA-N C=C/C=C(/CCCN(CC1)CCN1C(c(cc1)cc(OC(F)(F)F)c1NS(c1cccc2c1nccc2)(=O)=O)=O)\C=C Chemical compound C=C/C=C(/CCCN(CC1)CCN1C(c(cc1)cc(OC(F)(F)F)c1NS(c1cccc2c1nccc2)(=O)=O)=O)\C=C CUWMMYFPUKXUKK-GZIVZEMBSA-N 0.000 description 1
- WIWMGDGHUBIGQE-UHFFFAOYSA-N C=[I]c1cc(Cl)cc(CN(CC2)CCN2C(c(cc2OC(F)(F)F)ccc2NS(=O)=O)=O)c1 Chemical compound C=[I]c1cc(Cl)cc(CN(CC2)CCN2C(c(cc2OC(F)(F)F)ccc2NS(=O)=O)=O)c1 WIWMGDGHUBIGQE-UHFFFAOYSA-N 0.000 description 1
- FMLPQHJYUZTHQS-UHFFFAOYSA-N CC(C1)NCCN1C(OC(C)(C)C)=O Chemical compound CC(C1)NCCN1C(OC(C)(C)C)=O FMLPQHJYUZTHQS-UHFFFAOYSA-N 0.000 description 1
- NDUURDFTSPYVKW-UHFFFAOYSA-N CC(CN(CC1CCCC1)CC1)N1C(c(ccc(NS(=O)=O)c1)c1Cl)=O Chemical compound CC(CN(CC1CCCC1)CC1)N1C(c(ccc(NS(=O)=O)c1)c1Cl)=O NDUURDFTSPYVKW-UHFFFAOYSA-N 0.000 description 1
- NHYTWSQSLVYPOZ-UHFFFAOYSA-N CC(CN(CC1COCC1)CC1)N1C(c(cc1)ccc1NS(=O)=O)=O Chemical compound CC(CN(CC1COCC1)CC1)N1C(c(cc1)ccc1NS(=O)=O)=O NHYTWSQSLVYPOZ-UHFFFAOYSA-N 0.000 description 1
- OLEZEIWUFBLCOI-UHFFFAOYSA-N CC(CN(CC1OCCCC1)CC1)N1C(c(cc1)ccc1NS(=O)=O)=C(C)C Chemical compound CC(CN(CC1OCCCC1)CC1)N1C(c(cc1)ccc1NS(=O)=O)=C(C)C OLEZEIWUFBLCOI-UHFFFAOYSA-N 0.000 description 1
- ZBSYMYROECDZJU-UHFFFAOYSA-N CC(CN(Cc(c(F)c1)cc(F)c1F)CC1)N1C(c(cc1)ccc1NS(=O)=O)=O Chemical compound CC(CN(Cc(c(F)c1)cc(F)c1F)CC1)N1C(c(cc1)ccc1NS(=O)=O)=O ZBSYMYROECDZJU-UHFFFAOYSA-N 0.000 description 1
- HLRSCXPFFRCILA-UHFFFAOYSA-N CC(CN(Cc(c(F)cc(F)c1)c1F)CC1)N1C(c(ccc(NS(=O)=O)c1)c1Cl)=O Chemical compound CC(CN(Cc(c(F)cc(F)c1)c1F)CC1)N1C(c(ccc(NS(=O)=O)c1)c1Cl)=O HLRSCXPFFRCILA-UHFFFAOYSA-N 0.000 description 1
- AHKWNCXDRVTWQX-UHFFFAOYSA-N CC(CN(Cc(cc1)ccc1F)CC1)N1C(c(ccc(NS(=O)=O)c1)c1Cl)=O Chemical compound CC(CN(Cc(cc1)ccc1F)CC1)N1C(c(ccc(NS(=O)=O)c1)c1Cl)=O AHKWNCXDRVTWQX-UHFFFAOYSA-N 0.000 description 1
- NSYMPDFDSMYUIR-UHFFFAOYSA-N CC(CN(Cc(cc1F)cc(F)c1F)CC1C)N1C(c(cc1)ccc1NS(=O)=O)=O Chemical compound CC(CN(Cc(cc1F)cc(F)c1F)CC1C)N1C(c(cc1)ccc1NS(=O)=O)=O NSYMPDFDSMYUIR-UHFFFAOYSA-N 0.000 description 1
- GNPXMCPJHGMZJK-UHFFFAOYSA-N CC(CN(Cc1cc(F)cc(F)c1F)CC1C)N1C(c(cc1)ccc1NS(=O)=O)=O Chemical compound CC(CN(Cc1cc(F)cc(F)c1F)CC1C)N1C(c(cc1)ccc1NS(=O)=O)=O GNPXMCPJHGMZJK-UHFFFAOYSA-N 0.000 description 1
- YWXAARJNHGLODT-UHFFFAOYSA-N CC(c(c(F)c(cc1)F)c1F)N(CC1)CC(C)N1C(c(cc1)ccc1NS(=O)=O)=O Chemical compound CC(c(c(F)c(cc1)F)c1F)N(CC1)CC(C)N1C(c(cc1)ccc1NS(=O)=O)=O YWXAARJNHGLODT-UHFFFAOYSA-N 0.000 description 1
- DFQBOPCFSUDSQZ-OMZFTRSQSA-N CC/C=C(\C)/NS(c1cccc2c1N=CCCC=C2)(=O)=O Chemical compound CC/C=C(\C)/NS(c1cccc2c1N=CCCC=C2)(=O)=O DFQBOPCFSUDSQZ-OMZFTRSQSA-N 0.000 description 1
- ADAKKOMDBULNIN-UHFFFAOYSA-N CCC(COC)OC(N(CC1)CC(C)N1C(c(cc1)ccc1NS(=O)=O)=O)=O Chemical compound CCC(COC)OC(N(CC1)CC(C)N1C(c(cc1)ccc1NS(=O)=O)=O)=O ADAKKOMDBULNIN-UHFFFAOYSA-N 0.000 description 1
- XUUHHFSFLCXXBT-UHFFFAOYSA-N C[n]1cnc(CN(CC2)CCN2C(c(cc2OC(F)(F)F)ccc2NS(=O)=O)=O)c1 Chemical compound C[n]1cnc(CN(CC2)CCN2C(c(cc2OC(F)(F)F)ccc2NS(=O)=O)=O)c1 XUUHHFSFLCXXBT-UHFFFAOYSA-N 0.000 description 1
- WQKFFZGREJJXTG-UHFFFAOYSA-N Cc(nc1)cnc1C(N(CC1)CCN1C(c(cc1)ccc1NS(=O)=O)=O)=O Chemical compound Cc(nc1)cnc1C(N(CC1)CCN1C(c(cc1)ccc1NS(=O)=O)=O)=O WQKFFZGREJJXTG-UHFFFAOYSA-N 0.000 description 1
- ZNYJSUKJOWETKU-UHFFFAOYSA-N Cc1cc(F)cc(C(N(CC2)CCN2C(c(cc2)ccc2NS(=O)=O)=O)=O)c1 Chemical compound Cc1cc(F)cc(C(N(CC2)CCN2C(c(cc2)ccc2NS(=O)=O)=O)=O)c1 ZNYJSUKJOWETKU-UHFFFAOYSA-N 0.000 description 1
- SCGPOBHJJNYCTN-UHFFFAOYSA-N O=C(c(cc1)cnc1NS(=O)=O)N1CCN(CC2CC2)CC1 Chemical compound O=C(c(cc1)cnc1NS(=O)=O)N1CCN(CC2CC2)CC1 SCGPOBHJJNYCTN-UHFFFAOYSA-N 0.000 description 1
- NWFQKZXJXWGXKP-UHFFFAOYSA-N O=C(c(cc1C(F)(F)F)ccc1NS(=O)=O)N1CCN(Cc2ccncc2)CC1 Chemical compound O=C(c(cc1C(F)(F)F)ccc1NS(=O)=O)N1CCN(Cc2ccncc2)CC1 NWFQKZXJXWGXKP-UHFFFAOYSA-N 0.000 description 1
- MJGVGNMYEJRRNB-UHFFFAOYSA-N O=C(c(cc1OC(F)(F)F)ccc1NS(=O)=O)N1CCN(CC2CCCC2)CC1 Chemical compound O=C(c(cc1OC(F)(F)F)ccc1NS(=O)=O)N1CCN(CC2CCCC2)CC1 MJGVGNMYEJRRNB-UHFFFAOYSA-N 0.000 description 1
- GOCJGLZXRQGEMN-UHFFFAOYSA-N O=C(c(cc1OC(F)(F)F)ccc1NS(=O)=O)N1CCN(CCc(ccnc2)c2F)CC1 Chemical compound O=C(c(cc1OC(F)(F)F)ccc1NS(=O)=O)N1CCN(CCc(ccnc2)c2F)CC1 GOCJGLZXRQGEMN-UHFFFAOYSA-N 0.000 description 1
- KYOMBKBEBHHERB-UHFFFAOYSA-N O=C(c(ccc(NS(=O)=O)c1)c1Cl)N1CCN(Cc(c(F)c2)cc(F)c2F)CC1 Chemical compound O=C(c(ccc(NS(=O)=O)c1)c1Cl)N1CCN(Cc(c(F)c2)cc(F)c2F)CC1 KYOMBKBEBHHERB-UHFFFAOYSA-N 0.000 description 1
- LNRQAQVZIFYRBZ-UHFFFAOYSA-N O=C(c(nc1)cnc1NS(=O)=O)N1CCN(Cc(cc2)ccc2F)CC1 Chemical compound O=C(c(nc1)cnc1NS(=O)=O)N1CCN(Cc(cc2)ccc2F)CC1 LNRQAQVZIFYRBZ-UHFFFAOYSA-N 0.000 description 1
- MBTZFKWICAIMHN-UHFFFAOYSA-N O=C(c1c[s]cn1)N(CC1)CCN1C(c(cc1OC(F)(F)F)ccc1NS(=O)=O)=O Chemical compound O=C(c1c[s]cn1)N(CC1)CCN1C(c(cc1OC(F)(F)F)ccc1NS(=O)=O)=O MBTZFKWICAIMHN-UHFFFAOYSA-N 0.000 description 1
- WETHWBWDEMTTMV-UHFFFAOYSA-N O=C(c1ncc[s]1)N(CC1)CCN1C(c(cc1)ccc1NS(=O)=O)=O Chemical compound O=C(c1ncc[s]1)N(CC1)CCN1C(c(cc1)ccc1NS(=O)=O)=O WETHWBWDEMTTMV-UHFFFAOYSA-N 0.000 description 1
- GDUHYJFJTXACNF-UHFFFAOYSA-N OC1(C(c2cccc3c2nccc3)OC1)Cl Chemical compound OC1(C(c2cccc3c2nccc3)OC1)Cl GDUHYJFJTXACNF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482166P | 2011-05-03 | 2011-05-03 | |
| PCT/US2012/036413 WO2012151452A1 (en) | 2011-05-03 | 2012-05-03 | Pyruvate kinase activators for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2746558T3 true ES2746558T3 (es) | 2020-03-06 |
Family
ID=46085224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12721111T Active ES2746558T3 (es) | 2011-05-03 | 2012-05-03 | Activadores de piruvato cinasa R para uso en terapia |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9404081B2 (enExample) |
| EP (1) | EP2704720B1 (enExample) |
| JP (2) | JP6267112B2 (enExample) |
| CN (1) | CN103608016A (enExample) |
| AU (1) | AU2012250690B2 (enExample) |
| CA (1) | CA2834692A1 (enExample) |
| ES (1) | ES2746558T3 (enExample) |
| WO (1) | WO2012151452A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010223919B2 (en) | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
| CN102448951B (zh) | 2009-04-06 | 2017-05-10 | 安吉奥斯医药品有限公司 | 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法 |
| NZ597379A (en) | 2009-06-29 | 2014-04-30 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
| EP3064595B1 (en) | 2009-10-21 | 2019-02-27 | Agios Pharmaceuticals, Inc. | Methods for cell-proliferation-related disorders |
| CA2822432C (en) | 2010-12-21 | 2019-09-24 | Agios Pharmaceuticals, Inc. | Bicyclic pkm2 activators |
| TWI549947B (zh) * | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| WO2012151452A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use in therapy |
| PH12017501176B1 (en) | 2011-05-03 | 2023-03-08 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| WO2014164749A1 (en) | 2013-03-13 | 2014-10-09 | Forma Therapeutics, Inc. | Novel compounds and compositions for inhibition of fasn |
| WO2014139144A1 (en) * | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CA2917671A1 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| KR20220070066A (ko) | 2014-03-14 | 2022-05-27 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| FR3030516B1 (fr) * | 2014-12-19 | 2019-12-27 | Galderma Research & Development | Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
| SI3307271T1 (sl) * | 2015-06-11 | 2023-11-30 | Agios Pharmaceuticals, Inc. | Postopki za uporabo aktivatorjev piruvat kinaze |
| US10653710B2 (en) | 2015-10-15 | 2020-05-19 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| PT3362065T (pt) | 2015-10-15 | 2024-06-21 | Servier Lab | Terapia de combinação compreendendo ivosidenib, citarabina e daunorubicina ou idarubicina para o tratamento de leucemia mielóide aguda |
| TN2019000290A1 (en) | 2017-03-20 | 2021-05-07 | Forma Therapeutics Inc | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| SG11202001353PA (en) | 2017-08-15 | 2020-03-30 | Agios Pharmaceuticals Inc | Pyruvate kinase modulators and use thereof |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| JP7450610B2 (ja) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | ピルビン酸キナーゼｒの活性化 |
| BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| CA3129829A1 (en) * | 2019-02-13 | 2020-08-20 | Agios Pharmaceuticals, Inc. | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders |
| BR112022004715A2 (pt) | 2019-09-19 | 2022-06-14 | Forma Therapeutics Inc | Composições de ativação de piruvato quinase r (pkr) |
| CN111892599B (zh) * | 2020-08-14 | 2023-01-13 | 黄芳 | 一种2,5-二氮杂双环[2.2.2]辛烷-2-羧酸叔丁酯的合成方法 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| EP4147700A1 (en) * | 2021-09-08 | 2023-03-15 | LQT Therapeutics Inc. | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
| GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| US6313127B1 (en) | 1996-02-02 | 2001-11-06 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
| AU722662B2 (en) | 1996-05-20 | 2000-08-10 | Darwin Discovery Limited | Quinoline sulfonamides as TNF inhibitors and as PDE-IV inhibitors |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| MX226123B (es) | 1999-09-17 | 2005-02-07 | Millennium Pharm Inc | Benzamidas e inhibidores del factor xa relacionadas. |
| IL148698A0 (en) | 1999-09-17 | 2002-09-12 | Cor Therapeutics Inc | INHIBITORS OF FACTOR Xa |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| JP2004534017A (ja) | 2001-04-27 | 2004-11-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｂａｃｅのインヒビター |
| EP1412325A1 (en) | 2001-06-11 | 2004-04-28 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| DE602004027171D1 (de) | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
| GB0412526D0 (en) | 2004-06-05 | 2004-07-14 | Leuven K U Res & Dev | Type 2 diabetes |
| JP5149009B2 (ja) | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体 |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| WO2007008143A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| MX2008002723A (es) | 2005-08-26 | 2008-03-26 | Serono Lab | Derivados de pirazina y uso como inhibidores de p13k. |
| CA2669117A1 (en) | 2006-10-26 | 2008-05-02 | Gary A. Flynn | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
| HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| KR101472765B1 (ko) | 2006-12-08 | 2014-12-15 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 경구용 Ｘａ 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Ｘａ 인자 억제제를 사용하는 혈전증의 치료 방법 |
| AU2010223919B2 (en) | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
| ES2619557T3 (es) | 2009-05-04 | 2017-06-26 | Agios Pharmaceuticals, Inc. | Activadores de PKM2 para uso en el tratamiento del cáncer |
| WO2010130638A1 (en) | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| NZ597379A (en) | 2009-06-29 | 2014-04-30 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
| CA2773561A1 (en) | 2009-09-14 | 2011-03-17 | Phusis Therapeutics Inc. | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
| CN102574843B (zh) | 2009-10-22 | 2015-06-17 | 法博太科制药有限公司 | 抗纤维化剂的稠环类似物 |
| BR112012021806A2 (pt) * | 2010-03-01 | 2015-09-08 | Myrexis Inc | compostos e seus usos terapêusticos. |
| FR2967674B1 (fr) | 2010-11-23 | 2012-12-14 | Pf Medicament | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| PH12017501176B1 (en) * | 2011-05-03 | 2023-03-08 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
| WO2012151452A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use in therapy |
-
2012
- 2012-05-03 WO PCT/US2012/036413 patent/WO2012151452A1/en not_active Ceased
- 2012-05-03 ES ES12721111T patent/ES2746558T3/es active Active
- 2012-05-03 JP JP2014509459A patent/JP6267112B2/ja not_active Expired - Fee Related
- 2012-05-03 CA CA2834692A patent/CA2834692A1/en not_active Abandoned
- 2012-05-03 CN CN201280028693.4A patent/CN103608016A/zh active Pending
- 2012-05-03 US US14/115,292 patent/US9404081B2/en not_active Expired - Fee Related
- 2012-05-03 EP EP12721111.8A patent/EP2704720B1/en active Active
- 2012-05-03 AU AU2012250690A patent/AU2012250690B2/en not_active Ceased
-
2016
- 2016-09-05 JP JP2016173166A patent/JP6267299B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016199597A (ja) | 2016-12-01 |
| JP6267299B2 (ja) | 2018-01-24 |
| AU2012250690B2 (en) | 2017-06-08 |
| CN103608016A (zh) | 2014-02-26 |
| US20140155408A1 (en) | 2014-06-05 |
| AU2012250690A1 (en) | 2013-11-14 |
| EP2704720A1 (en) | 2014-03-12 |
| EP2704720B1 (en) | 2019-08-07 |
| CA2834692A1 (en) | 2012-11-08 |
| US9404081B2 (en) | 2016-08-02 |
| JP6267112B2 (ja) | 2018-01-24 |
| JP2014513134A (ja) | 2014-05-29 |
| WO2012151452A1 (en) | 2012-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2746558T3 (es) | Activadores de piruvato cinasa R para uso en terapia | |
| US20250332161A1 (en) | Pyruvate kinase activators for use in therapy | |
| CN111201223A (zh) | SHP2的八氢环戊二烯并[c]吡咯别构抑制剂 | |
| WO2012151448A1 (en) | Pyruvate kinase activators for use in therapy | |
| HK1194985A (en) | Pyruvate kinase r activators for use in therapy | |
| HK1194985B (en) | Pyruvate kinase r activators for use in therapy | |
| HK40000845B (en) | Pyruvate kinase activators for use in therapy | |
| HK1194008B (en) | Pyruvate kinase activators for use in therapy |